

# Gary J Doherty

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6299664/gary-j-doherty-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14 papers	389 citations	8 h-index	16 g-index
16 ext. papers	613 ext. citations	10.1 avg, IF	4.44 L-index

#	Paper	IF	Citations
14	Targeting senescent cells in translational medicine. <i>EMBO Molecular Medicine</i> , <b>2019</b> , 11, e10234	12	92
13	HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 13-22	3.6	85
12	Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity. <i>Aging Cell</i> , <b>2020</b> , 19, e13142	9.9	64
11	Activating HER2 mutations as emerging targets in multiple solid cancers. <i>ESMO Open</i> , <b>2017</b> , 2, e000279	6	62
10	Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. <i>Lancet Oncology</i> , <b>2020</b> , 21, 624-627	21.7	20
9	Cellular senescence in cancer: from mechanisms to detection. <i>Molecular Oncology</i> , <b>2021</b> , 15, 2634-2671	7.9	18
8	Rethinking cancer clinical trials for COVID-19 and beyond. <i>Nature Cancer</i> , <b>2020</b> , 1-5	15.4	16
7	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , <b>2019</b> , 88, 247-280	29.1	14
6	KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers. <i>Trends in Molecular Medicine</i> , <b>2017</b> , 23, 377-378	11.5	5
5	Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma. <i>Anti-Cancer Drugs</i> , <b>2019</b> , 30, 110-115	2.4	2
4	The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.. <i>BMC Cancer</i> , <b>2022</b> , 22, 99	4.8	2
3	Activatable senoprobes and senolytics: Novel strategies to detect and target senescent cells.. <i>Mechanisms of Ageing and Development</i> , <b>2022</b> , 202, 111618	5.6	2
2	Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review. <i>Current Problems in Cancer</i> , <b>2021</b> , 45, 100701	2.3	1
1	Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat.. <i>JCO Precision Oncology</i> , <b>2021</b> , 5, 1579-1583	3.6	0